Back HCV Populations

HCV Populations

PAS 2017: Sofosbuvir Plus Ribavirin Cures Teens with Genotype 2 or 3 Hepatitis C

A 2-drug regimen of sofosbuvir (Sovaldi) and ribavirin taken for 12 weeks led to sustained virological response in all treated adolescents with hepatitis C virus (HCV) genotype 2, while a 24-week course cured all but one teen with harder-to-treat genotype 3, according to a presentation at the 2017 Pediatric Academic Societies Meeting last week in San Francisco.

alt

Read more:

CROI 2017: Hepatitis C Treatment Can Be Provided Successfully at Syringe Exchange Sites

Administering direct-acting antiviral therapy for people who inject drugs at a syringe exchange site led to high sustained response rates in a pilot study in New York City, researchers reported at the recent Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. Expanding treatment for this population could reduce hepatitis C virus (HCV) transmission and ultimately help eliminate hepatitis C as a public health threat.

alt

Read more:

Coverage of 5th International Symposium on Hepatitis Care in Substance Users (INHSU 2016)

HIVandHepatitis.com coverage of the 5th International Symposium on Hepatitis Care in Substance Users (INHSU 2016), September 7-9 in Oslo, Norway.

Highlights include hepatitis C treatment for people who inject drugs and people in prison, extra-hepatic manifestations of hepatitis C, and development of an HCV vaccine.

INHSU 2016 coverage listing

INHSU 2016 website

9/3016

alt

BHIVA 2017: London Data Shows Hepatitis C Is Transmitted During Anal Sex Without Condoms

Around 1 in 5 HIV-positive gay men who recently acquired hepatitis C virus (HCV) report anal sex without a condom as the only behavior that could explain their infection. At the same time, a third of people acquiring HCV were gay men who did not have HIV, clinicians from the Mortimer Market Centre in London reported at the British HIV Association (BHIVA) conference last week in Liverpool. The data suggest that prevention messages around sexually transmitted hepatitis C need to change.

alt

Read more:

Interferon-Free Hepatitis C Treatment Safe and Effective for People Who Inject Drugs

Chronic hepatitis C patients on opioid substitution therapy, including those who continue to use illicit drugs, maintained good adherence and had high sustained response rates when treated with sofosbuvir/ledipasvir (Harvoni) or sofosbuvir/velpatasvir (Epclusa), according to a pair of ad-hoc analyses published in the August online edition of Clinical Infectious Diseases.

alt

Read more: